Lataa...
Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment. This retrospective cohort included patients hospitalized for a major bleed that result...
Tallennettuna:
| Julkaisussa: | Clin Appl Thromb Hemost |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7019392/ https://ncbi.nlm.nih.gov/pubmed/31876159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029619896619 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|